CK Hutchison-backed Sequencio to Release Preclinical Data on Cancer Vaccine, Combination Therapy Significantly Slows Tumor Growth
Sequencio Therapeutics, a subsidiary of CK Hutchison Holdings, has announced that it will present preclinical data for its cancer vaccine candidates CKLS118 and CKLS202 on Friday at the Society for Immunotherapy of Cancer (SITC) annual meeting in Phoenix, Arizona, US. The company's research found that when its circular RNA cancer vaccine CKLS118 is used in combination with a PD-1 inhibitor, the tumor growth inhibition rate reaches up to 88.9%, compared to 68.6% when the PD-1 inhibitor is used alone.
CK Hutchison-backed Sequencio to Release Preclinical Data on Cancer Vaccine, Combination Therapy Significantly Slows Tumor Growth
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Lombard (BARD) Token Analysis: Value, Investment Potential, and Risk Assessment
-
2
A Review of Major Global Digital Currency Trading Platforms and Market Landscape
-
3
Bitcoin Leveraged Trading Analysis: Definition, Operations, and Risk Management
-
4
A Rundown of Major Global Crypto Exchanges and Fee Comparison: How to Choose a Low-Cost Platform?
-
5
WSI Token: Role and Future Outlook of the WeSendit Decentralized File Sharing Platform
-
6
TATA Coin: Value and Long-Term Investment Considerations for a Community-Driven Token
-
7
SKL (SKALE): Ethereum Scaling, AI Agent Deployment, and Governance Dynamics Analysis
-
8
The Digital Currency Era: Fintech's Opportunities and Challenges Coexist
-
9
FLOKI Token Burn Mechanism Analysis and Price Outlook: Can it Reach $1?
-
10
Ethereum falls to a three-year low of $1,571, down approximately 68% from its all-time high.
Markets Today
Recommended Reading







